Methods for providing compositions to corn fields prior to harvesting are provided herein. These methods provide an extended time period for the use of lower height or standard height farm equipment in-season in corn fields, while reducing the risk of damage to the corn plants. These methods also allow for late season access with lower height or standard height farm equipment, while reducing the risk of damage to the corn plants.

Methods for providing compositions to corn fields prior to harvesting are provided herein. These methods provide an extended time period for the use of lower height or standard height farm equipment in-season in corn fields, while reducing the risk of damage to the corn plants. These methods also allow for late season access with lower height or standard height farm equipment, while reducing the risk of damage to the corn plants.

The present disclosure provides anti-LAG-3 heavy-chain antibody or the antigen-binding domain thereof, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the uses thereof.

The present invention concerns a new gene therapy approach to increase light-sensitivity in degenerating cones in advanced stages of rod-cone dystrophy (RCD) mediated by G-protein-gated-K+ channel (GIRK), in particular GIRK2, activated by G proteins recruited by cone opsin expressed in degenerating cones.

Chimeric transmembrane immunoreceptors (CAR) targeted to PSCA are described.

Chimeric transmembrane immunoreceptors (CAR) targeted to PSCA are described.

A method of inducing genetic recombination, including: allowing a protein having DNA double-stranded cleavage activity to act in cells of a eukaryotic organism which is a polyploidy inherently possessed by a eukaryotic organism. In eukaryotic organisms, various genetic recombination generates new genome set composition. This is done to obtain a population of eukaryotic organisms that hold the modified genomic set.

Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated RAS amino acid sequence presented by a human leukocyte antigen (HLA) Class I molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.

Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated RAS amino acid sequence presented by a human leukocyte antigen (HLA) Class I molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.

The present disclosure relates to antibodies that bind human CD19 (“anti-human CD19 antibodies” or “anti-human CD19 antibodies”), compositions comprising such anti-human CD19 antibodies, and methods of using such anti-human CD19 antibodies.